サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1378953

抗生物質市場レポート：作用機序、薬剤クラス別、活性スペクトル、投与経路、エンドユーザー、地域別、2023-2028年

Antibiotics Market Report by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗生物質市場レポート：作用機序、薬剤クラス別、活性スペクトル、投与経路、エンドユーザー、地域別、2023-2028年
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の抗生物質市場規模は2022年に494億米ドルに達しました。今後、IMARC Groupは、2028年には626億米ドルに達し、2022～2028年の成長率（CAGR）は4.0%になると予測しています。肺炎、結核、その他の感染症が個人の間で蔓延していること、抗菌薬耐性（AMR）の発生が増加していること、バイオテクノロジーと創薬技術の技術的進歩が市場を推進している主な要因の一部です。

抗生物質は、細菌感染を治療するために使用される医薬品の一種です。錠剤、カプセル剤、注射剤、クリーム剤、軟膏剤など、さまざまな形態で広く販売されています。細菌を死滅させるか、増殖を抑制して感染症を効果的に除去します。細菌細胞内の特定のメカニズムや構造を標的とし、その重要な機能を阻害して繁殖を阻止します。これに加えて、抗生物質は個人の免疫システムを強化する手助けをします。その結果、抗生物質は、尿路感染症（UTI）、呼吸器感染症、皮膚感染症、特定の性感染症など、様々な病気の治療に利用されています。

現在、世界中の大衆の間で多くの慢性疾患の有病率が増加していることが、市場の成長に寄与しています。さらに、世界中のオンラインショップやオフラインショップを通じて抗生物質が広く入手可能であることが、市場の成長を強化しています。これとは別に、外用抗生物質が個人の手術部位感染のリスクを最小限に抑えることから、外用抗生物質に対する需要の高まりが市場にプラスの影響を与えています。さらに、家畜の健康と福祉を守り、食の安全をサポートするために、畜産において抗生物質の使用が増加していることが、市場の成長を強化しています。これに伴い、老年人口における抗生物質需要の増加が市場の成長を支えています。さらに、予防ヘルスケア対策に対する消費者の意識の高まりが、市場の成長を後押ししています。

抗生物質市場の動向と促進要因：

感染症の流行増加

世界中の大衆の間で、肺炎、結核、尿路感染症（UTI）、消化管感染症、敗血症などの感染症の流行が増加しています。不衛生が細菌感染症の蔓延を助長しているため、人々はますますこれらの病気に苦しむようになっています。さらに、薬剤耐性菌の出現が抗生物質の需要を増大させています。このような感染症の治療を助ける効果的な抗生物質の需要が増加しています。抗生物質は、細菌感染をターゲットにし、除去するために特別に設計されています。体内の細菌を効果的に死滅させ、個人の治癒を促進します。さらに、抗生物質は患者の転帰を最適化するために医療専門家の指導の下で使用されます。

抗菌薬耐性（AMR）の増加

世界中で抗菌薬耐性（AMR）の発生が増加しており、抗生物質市場を牽引しています。AMRは、細菌、ウイルス、寄生虫、真菌が進化し、それらの治療に使用される薬剤に対して耐性を持つようになることで発生します。AMRは抗生物質の有効性を低下させ、感染症の長期化、重症化、ヘルスケアコストの増大、死亡率の上昇を引き起こします。抗生物質の乱用や誤用が薬剤耐性菌の発生を助長し、従来の抗生物質が効きにくくなっています。さらに、メチシリン耐性黄色ブドウ球菌（MRSA）やカルバペネム耐性腸内細菌科細菌（CRE）のような多剤耐性株が蔓延しています。このため、これらの耐性株と闘うための新しい抗生物質や代替治療法の開発が必要となっています。

抗生物質の技術的進歩

バイオテクノロジー、分子生物学、創薬技術の革新は、抗生物質開発の効率と効果の向上に役立っています。ゲノミクスとハイスループットスクリーニングは、潜在的な薬物標的の同定と大規模な化合物ライブラリーのスクリーニングを可能にします。さらに、コンピューター支援型ドラッグ・デザインは、薬効の予測や抗生物質候補の最適化を可能にします。これらの技術的進歩は抗生物質探索プロセスを合理化し、従来の方法に関連する時間とコストを削減します。さらに、迅速な病原体同定や感受性試験などの診断技術の進歩は、適切な抗生物質の選択と処方を支援し、患者の転帰を向上させる。さらに、技術の進歩は、感染症や抗菌剤耐性に対処するため、より強力な新しい抗生物質の開発を支援しています。

本レポートで扱う主な質問

  • 世界の抗生物質市場の規模は？
  • 2023-2028年における世界の抗生物質市場の予想成長率は？
  • 世界の抗生物質市場を牽引する主な要因は何か
  • COVID-19が世界の抗生物質市場に与えた影響は？
  • 抗生物質の世界市場における作用機序別の区分は？
  • 薬剤クラス別抗生物質の世界市場内訳は？
  • 抗生物質の世界市場の活性スペクトラムに基づく区分は？
  • 投与経路に基づく抗生物質の世界市場内訳は？
  • エンドユーザーに基づく抗生物質の世界市場内訳は？
  • 抗生物質の世界市場における主要地域は？
  • 抗生物質の世界市場における主要プレーヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 抗生物質の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：作用機序別

  • 細胞壁合成阻害剤
    • 市場動向
    • 市場予測
  • タンパク質合成阻害剤
    • 市場動向
    • 市場予測
  • DNA合成阻害剤
    • 市場動向
    • 市場予測
  • RNA合成阻害剤
    • 市場動向
    • 市場予測
  • マイコール酸阻害剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • セファロスポリン
    • 市場動向
    • 市場予測
  • ペニシリン
    • 市場動向
    • 市場予測
  • フルオロキノロン
    • 市場動向
    • 市場予測
  • マクロライド
    • 市場動向
    • 市場予測
  • カルバペネム
    • 市場動向
    • 市場予測
  • アミノグリコシド
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：活性スペクトラム別

  • 広域スペクトラム抗生物質
    • 市場動向
    • 市場予測
  • ナロースペクトラム抗生物質
    • 市場動向
    • 市場予測

第9章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 非経口
    • 市場動向
    • 市場予測
  • 局所
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第11章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Allergan Plc（AbbVie Inc.）
    • Basilea Pharmaceutica AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Melinta Therapeutics
    • Merck & Co. Inc.
    • Nabriva Therapeutics Plc
    • Paratek Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Spero Therapeutics
    • Tetraphase Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Antibiotics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Antibiotics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Antibiotics Market: Breakup by Action Mechanism (in %), 2022
  • Figure 5: Global: Antibiotics Market: Breakup by Drug Class (in %), 2022
  • Figure 6: Global: Antibiotics Market: Breakup by Spectrum of Activity (in %), 2022
  • Figure 7: Global: Antibiotics Market: Breakup by Route of Administration (in %), 2022
  • Figure 8: Global: Antibiotics Market: Breakup by End User (in %), 2022
  • Figure 9: Global: Antibiotics Market: Breakup by Region (in %), 2022
  • Figure 10: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Antibiotics (Protein Synthesis Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Antibiotics (Protein Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Antibiotics (DNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Antibiotics (DNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Antibiotics (RNA Synthesis Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Antibiotics (RNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Antibiotics (Mycolic Acid Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Antibiotics (Mycolic Acid Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Antibiotics (Other Action Mechanisms) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Antibiotics (Other Action Mechanisms) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Antibiotics (Cephalosporin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Antibiotics (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Antibiotics (Penicillin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Antibiotics (Penicillin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Antibiotics (Fluoroquinolone) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Antibiotics (Fluoroquinolone) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Antibiotics (Macrolide) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Antibiotics (Macrolide) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Antibiotics (Carbapenem) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Antibiotics (Carbapenem) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Antibiotics (Aminoglycoside) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Antibiotics (Aminoglycoside) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Antibiotics (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Antibiotics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Antibiotics (Broad-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Antibiotics (Broad-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Global: Antibiotics (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Global: Antibiotics (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Global: Antibiotics (Parenteral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Global: Antibiotics (Parenteral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Global: Antibiotics (Topical) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Global: Antibiotics (Topical) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Global: Antibiotics (Other Routes of Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Global: Antibiotics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Global: Antibiotics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Global: Antibiotics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Global: Antibiotics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Global: Antibiotics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Global: Antibiotics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Global: Antibiotics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: North America: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: North America: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United States: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United States: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Canada: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Canada: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Asia-Pacific: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Asia-Pacific: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: China: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: China: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Japan: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Japan: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: India: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: India: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: South Korea: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: South Korea: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Australia: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Australia: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Indonesia: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Indonesia: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Others: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Europe: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Europe: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Germany: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Germany: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: France: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: France: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: United Kingdom: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: United Kingdom: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Italy: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Italy: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 86: Spain: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 87: Spain: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 88: Russia: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 89: Russia: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 90: Others: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 91: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Latin America: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 93: Latin America: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 94: Brazil: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 95: Brazil: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 96: Mexico: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 97: Mexico: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 98: Others: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 99: Others: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 100: Middle East and Africa: Antibiotics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 101: Middle East and Africa: Antibiotics Market: Breakup by Country (in %), 2022
  • Figure 102: Middle East and Africa: Antibiotics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 103: Global: Antibiotics Industry: SWOT Analysis
  • Figure 104: Global: Antibiotics Industry: Value Chain Analysis
  • Figure 105: Global: Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibiotics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Antibiotics Market Forecast: Breakup by Action Mechanism (in Million US$), 2023-2028
  • Table 3: Global: Antibiotics Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 4: Global: Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million US$), 2023-2028
  • Table 5: Global: Antibiotics Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 6: Global: Antibiotics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 7: Global: Antibiotics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 8: Global: Antibiotics Market: Competitive Structure
  • Table 9: Global: Antibiotics Market: Key Players
目次
Product Code: SR112023A3569

Abstract

The global antibiotics market size reached US$ 49.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 62.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.0% during 2022-2028. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.

Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.

At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market. Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.

Antibiotics Market Trends/Drivers:

Rising prevalence of infectious diseases

There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics. There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.

Increasing occurrence of antimicrobial resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.

Technological advancements in antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods. Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.

Antibiotics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

Cell Wall Synthesis Inhibitors

Protein Synthesis Inhibitors

DNA Synthesis Inhibitors

RNA Synthesis Inhibitors

Mycolic Acid Inhibitors

Others

Cell wall synthesis inhibitors represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the action mechanism. This includes cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. According to the report, cell wall synthesis represented the largest segment.

Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Breakup by Drug Class:

Cephalosporin

Penicillin

Fluoroquinolone

Macrolide

Carbapenem

Aminoglycoside

Others

Penicillin accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. According to the report, penicillin represented the largest segment.

Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Breakup by Spectrum of Activity:

Broad-Spectrum Antibiotics

Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics hold the biggest market share

The report has provided a detailed breakup and analysis of the market based on the spectrum of activity. This includes broad-spectrum antibiotics and narrow-spectrum antibiotics. According to the report, broad-spectrum antibiotics represented the largest segment.

Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Breakup by Route of Administration:

Oral

Parenteral

Topical

Others

Parenteral dominates the market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, parenteral, topical, and others. According to the report, parenteral represented the largest segment.

Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Breakup by End User:

Hospitals

Specialty Clinics

Others

Hospitals accounted for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty stores, and others. According to the report, hospitals represented the largest segment.

Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represented the largest market.

Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Allergan Plc (AbbVie Inc.)

Basilea Pharmaceutica AG

GlaxoSmithKline Plc

Johnson & Johnson

Melinta Therapeutics

Merck & Co. Inc.

Nabriva Therapeutics Plc

Paratek Pharmaceuticals Inc.

Pfizer Inc.

Sanofi SA

Spero Therapeutics

Tetraphase Pharmaceuticals

Recent Developments:

In 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline's (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.

In January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.

Key Questions Answered in This Report

  • 1. How big is the global antibiotics market?
  • 2. What is the expected growth rate of the global antibiotics market during 2023-2028?
  • 3. What are the key factors driving the global antibiotics market?
  • 4. What has been the impact of COVID-19 on the global antibiotics market?
  • 5. What is the breakup of the global antibiotics market based on the action mechanism?
  • 6. What is the breakup of the global antibiotics market based on the drug class?
  • 7. What is the breakup of the global antibiotics market based on the spectrum of activity?
  • 8. What is the breakup of the global antibiotics market based on the route of administration?
  • 9. What is the breakup of the global antibiotics market based on the end user?
  • 10. What are the key regions in the global antibiotics market?
  • 11. Who are the key players/companies in the global antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Action Mechanism

  • 6.1 Cell Wall Synthesis Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Protein Synthesis Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Synthesis Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 RNA Synthesis Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Mycolic Acid Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cephalosporin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Penicillin
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Fluoroquinolone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Macrolide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Carbapenem
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Aminoglycoside
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Spectrum of Activity

  • 8.1 Broad-Spectrum Antibiotics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Narrow-Spectrum Antibiotics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Topical
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Specialty Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Allergan Plc (AbbVie Inc.)
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica AG
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 GlaxoSmithKline Plc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Johnson & Johnson
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Melinta Therapeutics
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Merck & Co. Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Nabriva Therapeutics Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Paratek Pharmaceuticals Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Pfizer Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sanofi SA
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Spero Therapeutics
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
    • 16.3.12 Tetraphase Pharmaceuticals
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio